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The aim of this study was to determine the maximum tolerated dose of a ﬁxed dose of docetaxel when combined with
continuous infusion ifosfamide, with and without G-CSF support, in the treatment of advanced cancer, and to evaluate anti-
tumour activity of this combination. Thirty-one patients with advanced malignancies were treated with docetaxel 75 mg/m
2
intravenously on days 1, and ifosfamide at increasing dose levels from 1500 mg/m
2/day to 2750 mg/m
2/day as a continuous
infusion from day 1–3, every 3 weeks. A total of 107 cycles of treatment were administered. Without G-CSF support dose-
limiting toxicity of grade 4 neutropenia greater than 5 days duration occurred at dose level 1. With the addition of G-CSF the
maximum tolerated dose was docetaxel 75 mg/m
2 on day 1 and ifosfamide 2750 mg/m
2/day on days 1–3. Dose limiting
toxicity (DLT) included ifosfamide-induced encephalopathy, febrile neutropenia and grade three mucositis. Three complete
responses and 3 partial responses were seen. This combination of docetaxel and infusional ifosfamide is feasible and effective.
The recommended dose for future phase II studies is docetaxel 75 mg/m
2 on day 1 and ifosfamide 2500 mg/m
2/day
continuous infusion on days 1–3.
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Docetaxel and ifosfamide have both demonstrated signiﬁcant single
agent anti-tumour activity in a number of tumours. This phase I
study was performed to assess the feasibility, toxicity and maxi-
mum tolerated dose (MTD) of this combination.
Ifosfamide is an alkylating agent with activity in a variety of
solid tumours, including non-small cell lung cancer (NSCLC),
sarcoma, testicular cancer, breast cancer and lymphoma (Pinedo
and Verweij, 1986; Shirinian et al, 1992; Kaye et al, 1998; Mosko-
witz et al, 1999). The major toxicities of ifosfamide include
myelosuppression and haemorrhagic cystitis. The incidence of
cystitis can be reduced with co-administration of mesna, which
functions as a regional detoxicant of acrolein, the urotoxic metabo-
lite of ifosfamide. Other side effects include nephrotoxicity,
encephalopathy, nausea, vomiting and alopecia. Encephalopathy
appears to be more common in patients receiving oral or bolus
ifosfamide and in patients with low serum albumin, low serum
potassium or renal dysfunction (Meanwell et al, 1986; Watkin et
al, 1989; Cerny et al, 1990).
The optimum dosing schedule for ifosfamide is still uncertain.
The pharmacokinetics of ifosfamide is schedule dependent, but
large inter-patient variability in ifosfamide pharmacokinetics and
metabolism is seen (Lind et al, 1990). It has been administered
orally or intravenously as bolus injection, short-term or continuous
infusion, and either in 1 day, or in divided doses over several days.
In this study ifosfamide was administered as a continuous infusion
over 3 days, as this schedule has been demonstrated to have a
lower incidence of haemorrhagic cystitis and neutropenia (Lind
et al, 1990).
Docetaxel is a semi-synthetic taxane with clinical activity in a
wide range of tumours (Pazdur et al, 1992; Ravdin et al, 1995;
Kavanagh et al, 1996; Roth et al, 2000; Shepherd et al, 2000; Kaye
2001; Nabholtz et al, 2001; Aihara et al, 2002; Smith et al, 2002).
The major dose limiting toxicity (DLT) is myelosuppression,
predominantly neutropenia, which is usually short lasting, dose
dependent and non-cumulative (Extra et al, 1993; Tomiak et al,
1994; Pronk et al, 1998). Other toxicities are usually mild and
easily managed or prevented. Fluid retention is a signiﬁcant and
well-documented cumulative side effect of docetaxel, which is
reduced by pre-medication with corticosteroids (Bizzari and Bail
1994). A ﬁxed dose of docetaxel was chosen because of concerns
regarding the toxicities of fatigue, neuropathy and ﬂuid retention
at doses 475 mg/m
2.
Although the DLT for both drugs is neutropenia, the absence of
other signiﬁcant overlapping toxicity and the availability of G-CSF
support renders this combination a potentially useful therapy for a
variety of advanced cancers.
The objectives of this phase I study were to identify the MTD of
docetaxel plus ifosfamide with and without G-CSF support, and to
characterize the toxicity proﬁle of the combination.
PATIENTS AND METHODS
Patient selection
Patients were enrolled onto this study if they met the following
criteria: histologically conﬁrmed advanced cancer, for which
other forms of therapy had failed or were considered inappropri-
ate; no more than one previous line of chemotherapy, 44 weeks
prior to enrollment; no prior exposure to a taxane or ifosfamide.
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mance status 42; expected survival duration of 53 months;
adequate bone marrow function (absolute neutrophil count
52.0610
9/l, platelets 5100610
9/l and Hb 5100 g/l); adequate
hepatic function (total bilirubin 516upper limit of normal
(ULN); AST and ALT 42.56ULN, ALP 456ULN (except in
presence of bone only metastases and other liver function tests
normal, if both AST and/or ALT 51.56ULN and ALP
52.56ULN patients were excluded)); adequate renal function
(serum creatinine 41.56ULN). Patients were excluded with
signiﬁcant co-morbid medical conditions; symptomatic peripheral
neuropathy 4grade 2 according to NCIC Common Toxicity
Criteria; and presence of CNS disease. The Research Ethics
Committee at each participating institution approved the study.
Written informed consent was obtained from all patients prior
to study entry.
Drug administration
Docetaxel (Taxotere; RP56976) was supplied in vials by Rhone-
Poulenc Rorer as a concentrated sterile solution containing 40 mg
in 1 ml or 80 mg in 2 ml polysorbate 80. The appropriate amount
of drug was diluted in 500 ml of 5% dextrose and administered as a
1-hour infusion at a ﬁxed dose of 75 mg/m
2 on day 1.
Ifosfamide was diluted in 3 litres of dextrose–saline with mesna
at an equimolar dose and administered as a 24-h continuous infu-
sion daily for 3 days, commencing immediately after completion of
docetaxel. An intravenous bolus dose of 500 mg mesna was given
immediately prior to commencing the ifosfamide infusion on day
1, and at completion of the treatment on day 3. Treatment cycles
were repeated every 3 weeks.
Premedication with dexamethasone orally at a dose of 8 mg at
13, 7, and 1 h prior to treatment and then at 12, 24, and 36 h
post therapy. Anti-emetics were administered as per physician
and institution preference. These usually included a 5HT3 antago-
nist.
Granulocyte-colony stimulating factor (G-CSF, Granocyte
1,
Amrad Australia) was administered at a dose 150 mg/m
2/day (=1
vial daily) to all patients prophylactically after all three patients
entered on level 1A experienced grade 4 neutropenia greater than
5 days duration during the ﬁrst cycle of treatment. G-CSF was
commenced on day 4 and continued until the absolute neutrophil
count was 510610
9/l at all other dose levels.
Dosage and dose escalation procedure
Docetaxel dose was ﬁxed at 75 mg/m
2, and ifosfamide dose was
escalated in groups of at least three patients according to a pre-
deﬁned schedule until the MTD was identiﬁed (see Table 2). Dose
escalation within patients was not permitted. Three patients were
recruited at each dose level. Before escalating to the next dose
level at least three patients should have received one cycle and
been observed for toxicity for 2 weeks. If one out of three patients
at any dose level developed a DLT, three more patients were
entered at that dose level. The MTD was deﬁned as the dose at
which three or more out of six patients developed a dose limiting
toxicity. Dose limiting toxicity was deﬁned as febrile neutropenia,
grade 4 neutropenia greater than 5 days duration, grade 4 throm-
bocytopenia, and any grade 3 potentially life threatening toxicity
occurring in cycle 1. The intention of the study was to treat at
full doses at each dose level and avoid dose reductions. If patients
experienced signiﬁcant toxicity other than the deﬁned dose limit-
ing events, treatment was delayed until recovery to grade 0–1,
and then restarted, for the subsequent cycles, at the dose level
below. All toxicity data was reported as per the initial dose level.
Toxicities were graded according to the NCIC Common Toxicity
Criteria.
Evaluation
Pre-treatment evaluation included a full medical history and physi-
cal examination, complete blood count, differential white blood cell
(WBC), biochemistry tests (serum electrolytes, renal function,
hepatic function, calcium, phosphate, glucose), electrocardiogram
and urinalysis. Disease assessment included routine chest radio-
graph, computerized tomography of chest, abdomen and pelvis,
and radionuclide bone scan as clinically indicated within 3 weeks
of commencing treatment.
Clinical review and serum biochemistry were repeated weekly
during the ﬁrst cycle of treatment and then every 3 weeks. A
neurological examination was performed at baseline and at the
beginning of each treatment cycle. Complete blood cell count
was undertaken twice weekly. Urinalysis was performed before,
during and after the ifosfamide infusion. Formal disease assessment
was performed after every two cycles of treatment. Tumour
response was classiﬁed according to standard World Health Orga-
nization criteria (Miller, et al, 1981).
RESULTS
Thirty-one patients were entered into the study. All patients were
evaluable for toxicity and 28 were evaluable for response. Patient
characteristics are shown in Table 1. The median age was 49 years
(range of 24–71). Eighteen patients were male and 13 were female.
Seventeen patients had not received prior chemotherapy while the
remainder had received one prior chemotherapy regimen. One
hundred and seven cycles of treatment were given over six dose
levels (median three cycles per patient, range 1–8, see Table 2).
Dose limiting toxicity was reported in cycle 1 at the following dose
levels: two episodes of encephalopathy at level 3; two episodes of
febrile neutropenia at level 4; and two episodes of febrile neutrope-
nia, two of encephalopathy, and one of mucositis at level 6
(docetaxel 75 mg/m
2 with ifosfamide 2750 mg/m
2/day), which
was deﬁned as the MTD.
Haematological toxicity
Neutropenia grades 3 and 4 were experienced at all dose levels
(Table 3). At level 1A, all three patients had grade 4 neutropenia
lasting greater than 5 days, so prophylactic G-CSF was incorpo-
rated into the treatment of all future patients as planned. The
severity of neutropenia was reduced at dose level 1, with G-CSF
support, compared to without G-CSF support. At all higher dose
levels the incidence of grade 3–4 neutropenia was ifosfamide dose
dependent, but the duration of grade 4 neutropenia was less than 5
days. There were 10 episodes (9%) of febrile neutropenia but no
septic deaths. Severe anaemia, grades 3 and 4, was seen in 17 cycles
(16%). Grade 3–4 thrombocytopenia was uncommon, occurring
in 7% of cycles at all dose levels.
Non-haematological toxicity
Signiﬁcant toxicities included nausea and vomiting, which was
severe (grade 3–4) in only 6% of cycles (Table 4). Six episodes
resulted in admission for intravenous ﬂuids. Alopecia was
universal. Mucositis was generally mild with only two episodes
of grade 3 mucositis at dose level 6. There were no episodes
of docetaxel induced peripheral oedema. There were no episodes
of grade 3 or 4 peripheral neuropathy. Most patients reported
mild fatigue.
Ifosfamide-related encephalopathy occurred in eight patients,
mainly at higher dose levels (level 3: two episodes, level 5: one
episode, level 6: ﬁve episodes). Most episodes resolved sponta-
neously following cessation of the ifosfamide, but one patient
required treatment with methylene blue. One episode was asso-
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lation with patient hypoalbuminaemia or hypokalaemia.
Responses
Twenty-eight of the 31 patients were assessable for response.
One patient received only one cycle of treatment and ceased
due to hepatic toxicity, compounded by the co-administration
of ketoconazole. Complete response (CR) was achieved in three
patients adenocarcinoma of oesophagus (duration of response 12
months), non-small cell lung cancer (18 months), and breast
cancer (8 months). Three patients had a partial response adeno-
carcinoma of oesophagus (6 months), adenocarcinoma of
unknown primary (7 months) and non-small cell lung cancer
(3 months).
DISCUSSION
In this study the MTD of the combination of docetaxel and ifosfa-
mide was identiﬁed at 75 mg/m
2 docetaxel on day 1 and 2750 mg/
m
2/day ifosfamide as a continuous infusion on days 1–3 with G-
CSF cover. The dose limiting toxicities included encephalopathy,
febrile neutropenia and mucositis.
The combination of docetaxel and ifosfamide is potentially effec-
tive in view of their non-cross resistant activity, and non-
overlapping toxicity except for neutropenia. The major toxicity, as
expected, was neutropenia, which was grade 3–4 neutropenia in
64% of cycles with 10 (9%) episodes of febrile neutropenia. Without
G-CSF support, the MTD was reached at level 1A. The use of G-CSF
allowed delivery of doses of each drug close to their single agent
MTD, and signiﬁcant non-haematological toxicity was then seen.
For this study we used a continuous infusion over three days
because of a low reported incidence of haemorrhagic cystitis and
myelosuppression compared with other schedules (Cerny et al,
1990; Lind et al, 1990). No instances of haemorrhagic cystitis were
observed in this study but myelosuppression was common and
dose-limiting as expected. We can speculate that other schedules
of ifosfamide may also be combined with docetaxel but the appro-
priate dose in such circumstances is unclear. This protocol
mandated a 3-day hospital admission, but administration using
an outpatient-based drug infusion may be feasible.
In a previous phase I study of this combination, Pronk et al
escalated the dose of both agents, and ifosfamide was infused over
a 24-h period on day 1 only (Pronk et al, 1998). In addition they
addressed the issue of scheduling, with docetaxel administered
prior to ifosfamide in the ﬁrst phase of the study, and reversal
of the order of administration in the second part. When ifosfamide
was given ﬁrst, there was a higher incidence of gastrointestinal
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Table 2 Dose levels
Dose Docetaxel Ifosfamide No. of No. cycles
level mg/m
2 mg/m
2/day* patients (range)
1A 75 1500 3 19 (4–8)
1 75 1500 3 11 (1–8)
2 75 1750 3 6 (1–3)
3 75 2000 7 24 (1–6)
4 75 2250 6 23 (2–8)
5 75 2500 3 8 (2–4)
6 75 2750 6 16 (1–5)
*Ifosfamide dose by continuous infusion per day, days 1–3
Table 1 Demographics
Patients treated 31
Age Median 49
Range 24–71
(ECOG) Performance Status 0 18
18
25
Sex Male 18
Female 13
Prior Chemotherapy Nil 17
Yes 14
Tumour type Lung 4
Renal 9
Oesophagus 4
Other 9
Unknown 5
Table 3 Haematological toxicity
1A 1 (+G)
Dose level (7G ) * @23456
No. of patients 3 3 3 7 6 3 6
No. of Cycles 19 11 6 24 23 8 16
Neutropenia
G d e 3 1 0 02201
(% cycles) (5%) (8%) (9%) (6%)
Gde 4 12 3 1 14 11 6 15
(% cycles) (63%) (27%) (16%) (58%) (48%) (75%) (94%)
Febrile neutropenia 0 0 0 4 2 0 4
Thrombocytopenia
Gde 1–2 3 6 1 10 4 4 10
(% cycles) (16%) (55%) (17%) (42%) (17%) (50%) (63%)
G d e 3 – 4 1 0 02014
(% cycles) (5%) (8%) (13%) (25%)
*; without G-CSF, @; with G-CSF
Table 4 Non-haematological toxicities
1 A 123456
No. of patients 3337636
No. of Cycles 19 11 6 24 23 8 16
Fatigue
Gde 1–2 8 8 1 18 14 6 9
(%) (42%) (73%) (17%) (75%) (61%) (75%) (56%)
G d e 3 – 4 3201003
(%) (16%) (18%) (4%) (33%)
Nausea/Vomiting
Gde 1–2 7 2 2 19 12 5 8
(%) (37%) (18%) (33%) (79%) (52%) (63%) (50%)
G d e 3 – 4 0012102
(%) (17%) (8%) (4%) (13%)
Constipation
G d e 1 – 2 310 1 1 514
(%) (16%) (9%) (46%) (22%) (13%) (25%)
G d e 3 – 4 0100200
(%) (9%) (9%)
Mucositis
G d e 1 – 2 3212214
(%) (16%) (18%) (17%) (8%) (22%) (13%) (25%)
G d e 3 – 4 0000002
(%) (13%)
Encephalopathy 0002015
Diarrhoea
G d e 1 – 2 4415303
(%) (21%) (36%) (17%) (21%) (13%) 0 (19%)
G d e 3 – 4 0100 0 0 00
(%) (9%)
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neutropenic fever (common to both schedules) occurred at a lower
dose when the ifosfamide was administered prior to docetaxel. The
MTD occurred at docetaxel 85 mg/m
2 and ifosfamide 5000 mg/m
2,
and the authors recommended that docetaxel be given prior to
ifosfamide. In contrast to our study, there were no episodes of ifos-
famide encephalopathy noted, and greater than 50% incidence of
mild peripheral neuropathy, possibly due to a higher cumulative
dose of docetaxel delivered (Pronk et al, 1998). It is difﬁcult to
compare different schedules of ifosfamide for relative efﬁcacy or
toxicity. However the total dose of ifosfamide deliverable in combi-
nation with 75 mg/m
2 docetaxel is greater with a 3-day infusion
(8500 mg/m
2) than with a 24-hour infusion (5000 mg/m
2).
Anti-tumour activity was seen at all dose levels. Of particular
interest were the responses seen in two of four patients with adeno-
carcinoma of the oesophagus, and in two of four patients with
non-small cell lung cancer.
In conclusion, the combination of docetaxel and infusional ifos-
famide for patients with advanced cancer is tolerable and effective.
The recommended dose for phase II studies is docetaxel 75 mg/m
2
day 1 and ifosfamide 2500 mg/m
2 on days 1–3 for previously
untreated, good performance status patients, and docetaxel
75 mg/m
2 and ifosfamide 2250 mg/m
2 for previously treated
patients. This schedule is worthy of further exploration in non-
small cell lung cancer and upper gastro-intestinal malignancies.
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